ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetPwC: Regulatory, Policy Uncertainty Constrain Dealmaking Life sciences deal volume and total valuation has been sluggish approaching the midpoint of 2025, even compared to the below-average numbers p
ScripWoodcock: Don’t Do The Wrong Study, Even If FDA Tells You To Janet Woodcock said she has told drug developers not to blindly follow agency advice, an unusual comment from a former US Food and Drug Adm
In VivoRising Leader 2025 recipient June Lanoue’s interest in science and health care took root at an early age. “I had human anatomy books when I was a little kid,” she shared. “My parents would yell at me